EP4712986A1 - Cellules immunitaires à récepteurs appariés et leurs utilisations - Google Patents

Cellules immunitaires à récepteurs appariés et leurs utilisations

Info

Publication number
EP4712986A1
EP4712986A1 EP24808210.9A EP24808210A EP4712986A1 EP 4712986 A1 EP4712986 A1 EP 4712986A1 EP 24808210 A EP24808210 A EP 24808210A EP 4712986 A1 EP4712986 A1 EP 4712986A1
Authority
EP
European Patent Office
Prior art keywords
receptor
antigen
cell
cells
inhibitory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24808210.9A
Other languages
German (de)
English (en)
Inventor
Timothy P. RILEY
Richele Martha BRUNO
Mark Erik DARIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A2 Biotherapeutics Inc
Original Assignee
A2 Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics Inc filed Critical A2 Biotherapeutics Inc
Publication of EP4712986A1 publication Critical patent/EP4712986A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgation propose des cellules immunitaires à récepteurs appariés et des procédés de fabrication et d'utilisation de celles-ci pour le traitement du cancer.
EP24808210.9A 2023-05-18 2024-05-17 Cellules immunitaires à récepteurs appariés et leurs utilisations Pending EP4712986A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363503133P 2023-05-18 2023-05-18
US202363608567P 2023-12-11 2023-12-11
PCT/US2024/030032 WO2024238962A1 (fr) 2023-05-18 2024-05-17 Cellules immunitaires à récepteurs appariés et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4712986A1 true EP4712986A1 (fr) 2026-03-25

Family

ID=93519893

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24808210.9A Pending EP4712986A1 (fr) 2023-05-18 2024-05-17 Cellules immunitaires à récepteurs appariés et leurs utilisations

Country Status (2)

Country Link
EP (1) EP4712986A1 (fr)
WO (1) WO2024238962A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006575A1 (fr) * 2024-06-26 2026-01-02 A2 Biotherapeutics, Inc. Cellules immunitaires avec récepteurs appariés et utilisations dans le traitement de l'auto-immunité

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022040454A1 (fr) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions et méthodes de traitement de cancers positifs à la mésothéline
KR20230153529A (ko) * 2021-02-19 2023-11-06 프리트 엠. 쇼드하리 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체

Also Published As

Publication number Publication date
WO2024238962A1 (fr) 2024-11-21

Similar Documents

Publication Publication Date Title
US12037377B2 (en) LILRB1-based chimeric antigen receptor
CA3150071A1 (fr) Recepteurs de surface cellulaire sensibles a la perte d'heterozygosite
US12435124B2 (en) Compositions and methods for treating CEACAM positive cancers
JP7621461B2 (ja) Ｅｇｆｒ陽性がんを治療するための組成物及び方法
AU2021329371A1 (en) Compositions and methods for treating mesothelin positive cancers
WO2022040470A1 (fr) Compositions et méthodes de traitement de cancers positifs à ceacam
JP2024507129A (ja) Ｈｅｒ２陽性がんを治療するための組成物及び方法
WO2022036065A2 (fr) Compositions et méthodes pour le traitement de cancers
WO2021252635A1 (fr) Compositions et méthodes de traitement de cancers
WO2024238962A1 (fr) Cellules immunitaires à récepteurs appariés et leurs utilisations
CN116635043A (zh) 用于治疗egfr阳性癌症的组合物和方法
US20250177445A1 (en) Engineered receptors specific to hla-e and methods of use
HK40080722B (en) Compositions and methods for treating egfr positive cancers
HK40080722A (en) Compositions and methods for treating egfr positive cancers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR